Literature DB >> 30742809

Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality.

Benjamin Loeh1, Lukas T Brylski1, Daniel von der Beck1, Werner Seeger2, Ekaterina Krauss3, Philippe Bonniaud4, Bruno Crestani5, Carlo Vancheri6, Athol U Wells7, Philipp Markart8, Andreas Breithecker9, Andreas Guenther10.   

Abstract

BACKGROUND: In this study, we retrospectively assessed the relationships among physiologic measurements, survival, and quantitative high-resolution CT (HRCT) scanning indexes in patients with idiopathic pulmonary fibrosis (IPF).
METHODS: Seventy patients (48 male; mean [SD] age, 66.4 [9.0] years) with IPF were enrolled in the study. After segmentation of the lungs in thin-section CT scanning with the patient in the supine position at full inspiration, we assessed following parameters: mean lung attenuation (MLA), skewness, kurtosis, peak attenuation, total lung area, inflexion point with slope, and area right of the inflexion point (AROIP). Additionally, FVC, FEV1, total lung capacity, diffusing capacity or transfer factor of the lung for carbon monoxide (Dlco), and 6-min walk distance were analyzed. Univariate and multivariate analysis were used for the prediction of physiologic outcomes by HRCT scanning indexes and then were correlated to survival in a proportional hazards analysis.
RESULTS: The strongest correlation was observed between MLA and FEV1, with an r of -0.63. MLA, peak attenuation, slope, attenuation, and AROIP correlated negatively with all physiologic measurements. AROIP was the best predictor of Dlco. Analysis for prediction of mortality showed that AROIP, kurtosis, and FVC were related significantly to survival. Multivariate regression revealed a significant impact of only AROIP (among age, sex, MLA, skewness, kurtosis, FVC, and Dlco) on survival.
CONCLUSIONS: These data indicate that HRCT scanning indexes are correlated to physiologic measurements. The newly defined parameter, AROIP, is of additive value for prediction of outcome. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02951416; URL: www.clinicaltrials.gov.
Copyright © 2019 American College of Chest Physicians. All rights reserved.

Entities:  

Keywords:  CT densitometry; HRCT index; disease prediction parameters; idiopathic pulmonary fibrosis

Mesh:

Year:  2019        PMID: 30742809     DOI: 10.1016/j.chest.2019.01.019

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Quantitative Computed Tomography: What Clinical Questions Can it Answer in Chronic Lung Disease?

Authors:  Marcelo Cardoso Barros; Stephan Altmayer; Alysson Roncally Carvalho; Rosana Rodrigues; Matheus Zanon; Tan-Lucien Mohammed; Pratik Patel; Al-Ani Mohammad; Borna Mehrad; Jose Miguel Chatkin; Bruno Hochhegger
Journal:  Lung       Date:  2022-06-25       Impact factor: 3.777

2.  Automated CT Lung Density Analysis of Viral Pneumonia and Healthy Lungs Using Deep Learning-Based Segmentation, Histograms and HU Thresholds.

Authors:  Andrej Romanov; Michael Bach; Shan Yang; Fabian C Franzeck; Gregor Sommer; Constantin Anastasopoulos; Jens Bremerich; Bram Stieltjes; Thomas Weikert; Alexander Walter Sauter
Journal:  Diagnostics (Basel)       Date:  2021-04-21

3.  Several specific high-resolution computed tomography patterns correlate with survival in patients with idiopathic pulmonary fibrosis.

Authors:  Minna E Mononen; Hannu-Pekka Kettunen; Sanna-Katja Suoranta; Miia S Kärkkäinen; Tuomas A Selander; Minna K Purokivi; Riitta L Kaarteenaho
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

4.  Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: Relationship with pulmonary function and clinical events.

Authors:  Masaki Suzuki; Naoko Kawata; Mitsuhiro Abe; Hajime Yokota; Rie Anazawa; Yukiko Matsuura; Jun Ikari; Shin Matsuoka; Kenji Tsushima; Koichiro Tatsumi
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

5.  Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank.

Authors:  Ekaterina Krauss; Maike Froehler; Maria Degen; Poornima Mahavadi; Ruth C Dartsch; Martina Korfei; Clemens Ruppert; Werner Seeger; Andreas Guenther
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

6.  Automatization and improvement of μCT analysis for murine lung disease models using a deep learning approach.

Authors:  Gerald Birk; Marc Kästle; Cornelia Tilp; Birgit Stierstorfer; Stephan Klee
Journal:  Respir Res       Date:  2020-05-24

7.  Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).

Authors:  Ekaterina Krauss; Silke Tello; Jochen Wilhelm; Johanna Schmidt; Mark Stoehr; Werner Seeger; Ruth C Dartsch; Bruno Crestani; Andreas Guenther
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

8.  NEDD4L-induced β-catenin ubiquitination suppresses the formation and progression of interstitial pulmonary fibrosis via inhibiting the CTHRC1/HIF-1α axis.

Authors:  Lin Chen; Yang Yang; Haiying Yan; Xiaying Peng; Jun Zou
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

9.  Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank.

Authors:  Ekaterina Krauss; Jana Haberer; Olga Maurer; Guillermo Barreto; Fotios Drakopanagiotakis; Maria Degen; Werner Seeger; Andreas Guenther
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241

10.  [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach.

Authors:  Bertrand Collin; Pierre-Simon Bellaye; Julie Tanguy; Françoise Goirand; Alexanne Bouchard; Jame Frenay; Mathieu Moreau; Céline Mothes; Alexandra Oudot; Alex Helbling; Mélanie Guillemin; Philippe Bonniaud; Alexandre Cochet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.